



CNMV
Markets Directorate General
C/ Edison núm. 4
28006 Madrid

Madrid, August 26, 2024

In accordance with article 227 of the Spanish Securities Markets and Investment Services Act (*Ley de los Mercados de Valores y de los Servicios de Inversión*), approved by Law 6/2023, of 17 March, and concordant provisions, articles 2.2 and 2.3 of the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 supplementing Regulation (EU) No 596/2014 of the European Parliament and of the Council with regard to regulatory technical standards for the conditions applicable to buy-back programmes and stabilisation measures and concordant provisions, is hereby reported the following

OTHER RELEVANT INFORMATION

Share buy-back, stabilisation and treasury stock programmes

In relation to the program to buy-back treasury shares announced by means of other relevant information communication dated April 30, 2024 (registration number 28360) (the "**Buy-back Program**"), Pharma Mar, S.A. (the "**Company**") hereby informs on the transactions carried out under the Buy-back Program during the period between August 19th and August 23rd of 2024 (the "**Period**").

Date	Security	Transaction	Stock Exchange	Number of shares	Average Price (€)
23/08/2024	PHM	Acquisition	BME	500	38.80000

Detailed information on each of the transactions carried out by the Company during the Period is attached as an annex.

ANNEX

Detailed information on treasury shares' acquisitions carried out during the Period.

Date	Security	Transaction	Stock Exchange	Number of shares	Average Price (€)	Broker
23/08/2024	PHM	Acquisition	BME	500	38.80000	JB Capital Markets, S.V. S.A.U